Regenerative Medicine: Does Erythropoietin have a Role?

Author(s): Michele Buemi, Antonio Lacquaniti, Giulia Maricchiolo, Davide Bolignano, Susanna Campo, Valeria Cernaro, Alessio Sturiale, Giovanni Grasso, Antoine Buemi, Alessandro Allegra, Valentina Donato, Lucrezia Genovese

Journal Name: Current Pharmaceutical Design

Volume 15 , Issue 17 , 2009

Become EABM
Become Reviewer
Call for Editor


Regenerative Medicine, a recent new medical domain, aims to develop new therapies through the stimulation of natural regenerative processes also in human beings. In this field, Erythropoietin (EPO) represents a significant subject of research. Several studies allow the assertion that EPO, in different concentrations, has protective effects mainly on the central nervous system, cardiovascular system and renal tissue. This action is carried out through one of few regenerative activities of human beings: angiogenesis. This mechanism, which involves endothelial stem cells and VEGF (Vascular Endothelial Growth Factor), has been experimentally demonstrated with Recombinant human erythropoietin (rHuEPO) and Darbepoetin, a long-acting EPO derivate. Furthermore, the demonstration of a cardiac production of EPO in Fugu rubripes and in Zebrafish has led cardiologists to “discover” Erythropoietin, postulating a hypothetical role in treatment of cardiovascular disease for this hormone. This is some of the experimental evidence which demonstrates that EPO can be in reason considered an important element of research of Regenerative Medicine and put in the network of drugs able to regenerate tissues and organs.

Keywords: Regenerative medicine, erythropoietin, angiogenesis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2009
Page: [2026 - 2036]
Pages: 11
DOI: 10.2174/138161209788453194
Price: $65

Article Metrics

PDF: 13